Printer Friendly

IMCERA'S MALLINCKRODT MEDICAL ANNOUNCES $15 MILLION EXPANSION AT RALEIGH, N.C., PLANT

 IMCERA'S MALLINCKRODT MEDICAL ANNOUNCES
 $15 MILLION EXPANSION AT RALEIGH, N.C., PLANT
 NORTHBROOK, Ill., June 9 /PRNewswire/ -- IMCERA Group Inc. (NYSE: IMA) announced today that its Mallinckrodt Medical unit will launch a $15 million expansion of its Raleigh, N.C., pharmaceutical plant to increase production capacity for diagnostic imaging products.
 The project, scheduled to begin this spring and be completed by mid- 1993, also is designed to improve operating efficiency and support development of new products. Total plant size will be increased by approximately one-third, to 133,000 square feet.
 "This expansion supports our strategic objective of pursuing continued global expansion, particularly with our Ultraject(R) syringe and non-ionic contrast media Optiray(R), while further penetrating the C-T scanning market domestically," said William J. Mercer, Mallinckrodt Medical, senior vice president of medical imaging.
 "This project also reflects our continued commitment to our customers worldwide, and to the employees of the Raleigh plant, who have consistently maintained the highest standards of quality and productivity," Mercer added.
 Chris Guerdan, plant manager, said the expansion is designed to meet increasing domestic demand and expand Mallinckrodt Medical's growth in international markets. The project will include:
 -- A new line to expand production of Ultraject plastic syringes which are prefilled with a single dose of X-ray contrast media. New production facilities will manufacture Ultraject syringes for power injectors, which are used during angiography and C-T scan procedures.
 -- A new, line to expand capacity for Mallinckrodt Medical X-ray contrast media offered in small volumes, generally 20 to 100 ml glass bottles. Included will be Optiray (Ioversol), the company's non-ionic agent which offers improved patient safety and tolerance compared to conventional X-ray contrast media.
 Guerdan said the project represents the third expansion at the Raleigh plant, which has been in operation since 1974. The plant employs about 150 people, with the expansion project expected to add 20 to 30 jobs.
 In the more than $3.7 billion worldwide radiology and cardiology market, which is expanding 12 percent annually, Mallinckrodt Medical is a leading developer and provider of specialized diagnostic products. Its major products are image-enhancing X-ray contrast media and diagnostic catheters.
 Mallinckrodt Medical, a St. Louis business unit of IMCERA, is a leading producer of products used in radiology, cardiology, nuclear medicine, anesthesiology and critical care procedures.
 A Fortune 250 company with fiscal 1991 net sales of more than $1.6 billion, IMCERA has two other international, technology-based businesses: Mallinckrodt Specialty Chemicals of Chesterfield, Mo., and Pitman-Moore of Lake Forest, Ill.
 Optiray (Ioversol) and Ultraject Fact Sheet
 Optiray
 Optiray is a non-ionic X-ray contrast medium that provides high- quality imaging and patient tolerance. Introduced by Mallinckrodt Medical, Inc., in 1989, it is the first contrast medium to be developed, patented and marketed by a U.S. pharmaceutical company.
 A low osmolality agent, Optiray has demonstrated greater safety and patient comfort, with significantly less heat and discomfort than conventional contrast media. It also has been shown to be more hydrophilic, or water-loving, compared to other non-ionic agents, making it less likely to enter cells or cross the blood brain barrier.
 Optiray is used for a broad range of cardiac and radiologic imaging procedures. Applications include computed tomography (C-T) scans to visualize organs and major blood vessels, urography and all major angiography procedures.


These include cerebral, peripheral and visceral arteriography, intra-arterial digital substraction angiography, venography, coronary arteriography, left ventriculography and pediatric indications.
 Ultraject
 Ultraject is an advanced packaging technology for the delivery of X-ray contrast media during cardiology and radiology imaging procedures. It consists of a plastic syringe pre-filled with a single dose of X-ray contrast media.
 An industry first, Ultraject is designed to provide greater convenience as well as less risk of contamination than the traditional method of transferring contrast media from a glass container into a syringe. Other benefits include reduced risk of needle sticks to medical personnel, less time required for each procedure and no contrast media waste when an exam is canceled.
 Introduced in 1990, the plastic syringes were developed by Mallinckrodt Medical using proprietary technology. Ultraject is offered as a hand-held syringe for IV contrast media procedures and also for use with power injectors during angiography and C-T scan procedures. The syringes are available in various sizes and with a variety of Mallinckrodt Medical contrast agents.
 -0- 6/9/92
 /CONTACT: Tura Cottingham, 708-205-2286, or (investors) Dave Prichard, 708-205-2270, both for IMCERA Group/
 (IMA) CO: IMCERA Group Inc. ST: Illinois IN: MTC SU:


CK -- NY037 -- 8368 06/09/92 12:25 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1992
Words:747
Previous Article:1992 GRAND TOUR ROAD RALLY RAISES $54,000 TO HELP UNDERPRIVILEGED YOUTH
Next Article:PSE&G $600 MILLION FIRST AND REFUNDING MORTGAGE BONDS RATED 'A' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
IMCERA'S BOARD OF DIRECTORS APPROVES $100 MILLION PROGRAM TO EXPAND MALLINCKRODT MEDICAL'S OPTIRAY PRODUCTION CAPACITY
MBI AND IMCERA'S MALLINCKRODT MEDICAL UNIT ANNOUNCE FILING OF NDS FOR ALBUNEX(R)
IMCERA REPORTS SIGNIFICANT INCREASE IN FISCAL 1993 FIRST QUARTER EARNINGS FROM CONTINUING OPERATIONS
IMCERA'S MALLINCKRODT MEDICAL UNIT AND SANDOZ PHARMA LTD. SIGN AGREEMENT TO SHARE MOLECULAR RESEARCH
IMCERA DISCUSSES REVIEW OF PITMAN-MOORE OPERATIONS; REVISES THIRD QUARTER AND FULL YEAR EPS EXPECTATIONS DUE TO PITMAN-MOORE PERFORMANCE
IMCERA'S BOARD OF DIRECTORS DECLARES QUARTERLY DIVIDENDS
OCTREOSCAN RELEASED FOR MARKETING IN UNITED STATES FOR IMAGING OF TUMORS AND METASTASES
MALLINCKRODT GROUP ANNOUNCES PLANS TO REPURCHASE STOCK
Mallinckrodt Acquires D. M. Graham Laboratories, Inc.
Mallinckrodt to Expand Hobart Facility

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters